Imagion Biosystems Limited (Imagion, ASX:IBX), is pleased to provide shareholders and interested parties an outline of its operational objectives as it moves toward first-in-human testing after the completion of its $12 million IPO and subsequent ASX listing.
Read the 12 July 2017 ASX Announcement.
Imagion Biosystems receives AU$3.5 million in R&D tax incentives
September 19, 2023
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it